Healthcare >> CEO Interviews >> September 13, 2002
MIKE GREY is the Chief Business Officer of Structural GenomiX, San
Diego, California. Structural GenomiX (SGX) is a drug discovery company
utilizing a genomics-driven, high-throughput structure-based platform to
increase the efficiency and effectiveness of the drug discovery process.
Between 1999 and 2001, Mr. Grey served as President and Chief Executive
Officer of Trega Biosciences, Inc. until its acquisition by Lion
Bioscience. Prior to joining Trega, Mr. Grey was President of BioChem
Therapeutics, Inc., a subsidiary of BioChem Pharma, Inc. from November
1994 to August 1998. In 1994, Mr. Grey was the President and Chief
Operating Officer for Ansan, Inc. From 1974 to 1993, Mr. Grey served in
various roles with Glaxo Holdings plc and Glaxo Inc., including
positions as Vice President, Corporate Development, and Director,
International Licensing. Mr. Grey serves on the Board of Directors of
Achillion Pharmaceuticals, Inc., Incellico Inc. and Epimmune, Inc. Mr.
Grey received a B.Sc. in Chemistry from the University of Nottingham,
UK. Profile
before we discuss recent developments?
Mr. Grey: Sure. SGX was formed in 1998, based on technology out of
Columbia
